New hope for hard-to-treat esophageal cancer?
NCT ID NCT05022654
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, SI-B001 and irinotecan, in people with advanced esophageal cancer that has come back or spread. The goal is to see if the combo can shrink tumors and control the disease. About 22 adults who have already tried standard treatments are taking part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anyang Cancer Hospital of Henan Province
Anyang, Henan, China
-
Beijing Cancer Hostital
Beijing, Beijing Municipality, 100142, China
-
Shanxi Cancer Hospital
Taiyuan, Shanxi, China
-
Suining Central Hospital
Suining, Sichuan, China
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
-
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.